NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06568172 2026-04-16
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06931717 2026-04-14
ARCH
ETOP IBCSG Partners Foundation
Phase 3 Recruiting
NCT06585410 2026-04-08
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06246916 2026-02-19
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting